Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091279 · ClinicalTrials.gov registry record · Phase 2
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
A Phase 2 study of Autism Spectrum Disorder and Aggression, sponsored by Jeremy Veenstra-vanderweele.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT07091279: Recruiting Phase 2 study of Autism Spectrum Disorder and Aggression, sponsored by Jeremy Veenstra-vanderweele.
NCT07091279 is a Phase 2 study of Autism Spectrum Disorder and Aggression that is actively recruiting participants, run by Jeremy Veenstra-vanderweele. The registered enrollment target is 60 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07091279, a Phase 2 study of Autism Spectrum Disorder and Aggression, is actively recruiting participants, sponsored by Jeremy Veenstra-vanderweele.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.
Primary Outcome
Any participant reported side effects or adverse events will be monitored through weekly medical monitoring visits with the study safety physician. Participants will complete blinded home monitoring of blood pressure and pulse on the first three days each dosing week (baseline through end of treatment phase at 12 weeks), and pre- and post-intervention Holter monitoring will be completed for dysrhythmias (at screening and week 6)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
Study Locations (2)
New York
- New York State Institute for Basic Research (IBR) - Staten Island
- Center for Autism and the Developing Brain - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07091279 shows while recruiting
NCT07091279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower).
The record links to 5 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07091279 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07091279 about?
NCT07091279 is a clinical study titled "Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism". The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-ali...
What is the current status of trial NCT07091279?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-01-22. Estimated completion is 2028-12.
What conditions does trial NCT07091279 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Aggression, Self-Injury, Challenging Behaviour, Severe Disruptive Behaviour Disorders.
What interventions are being tested in trial NCT07091279?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT07091279?
This trial is sponsored by Jeremy Veenstra-vanderweele, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091279 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07091279's enrollment target sits among peer trials
60 118th of 224 higher than 95 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI